Meditope Biosciences is revolutionizing the use of monoclonal antibodies. Our proprietary SnAP technology - Site-specific novel Antibody Platform - leverages a naturally occurring space in an antibody and carves it into a binding site. The result is a powerful technology platform that transforms antibodies into a "Lego-like" system, allowing for nearly anything imaginable to be easily, consistently, and controllably attached. SnAP enables the addition of limitless functionality to any monoclonal antibody, without affecting its ability to bind to a target. Driven by creativity and passion, we are a unique biotechnology company with the technology, team and strategy to succeed.